Tasimelteon Patent Expiration
Tasimelteon is Used for treating nighttime sleep disturbances in Smith-Magenis syndrome and non-24-hour sleep-wake disorder with tasimelteon. It was first introduced by Vanda Pharmaceuticals Inc
Tasimelteon Patents
Given below is the list of patents protecting Tasimelteon, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Hetlioz | US11759446 | Liquid tasimelteon formulations and methods of use thereof | Feb 21, 2041 | Vanda Pharms Inc |
| Hetlioz Lq | US11759446 | Liquid tasimelteon formulations and methods of use thereof | Feb 21, 2041 | Vanda Pharms Inc |
| Hetlioz Lq | US11202770 | Liquid tasimelteon formulations and methods of use thereof | Dec 11, 2040 | Vanda Pharms Inc |
| Hetlioz | US10179119 | Method of treatment | Aug 29, 2035 | Vanda Pharms Inc |
| Hetlioz | US11266622 | Method of treatment | Aug 29, 2035 | Vanda Pharms Inc |
| Hetlioz Lq | US10179119 | Method of treatment | Aug 29, 2035 | Vanda Pharms Inc |
| Hetlioz Lq | US11266622 | Method of treatment | Aug 29, 2035 | Vanda Pharms Inc |
| Hetlioz | US10376487 | Method of treatment | Jul 27, 2035 | Vanda Pharms Inc |
| Hetlioz Lq | US10376487 | Method of treatment | Jul 27, 2035 | Vanda Pharms Inc |
| Hetlioz | US10071977 | Highly purifid pharmaceutical grade tasimelteon | Feb 12, 2035 | Vanda Pharms Inc |
| Hetlioz | US10829465 | Highly purified pharmaceutical grade tasimelteon | Feb 12, 2035 | Vanda Pharms Inc |
| Hetlioz | US11566011 | Highly purified pharmaceutical grade tasimelteon | Feb 12, 2035 | Vanda Pharms Inc |
| Hetlioz | US11760740 | Highly purified pharmaceutical grade tasimelteon | Feb 12, 2035 | Vanda Pharms Inc |
| Hetlioz | US12049457 | Highly purified pharmaceutical grade tasimelteon | Feb 12, 2035 | Vanda Pharms Inc |
| Hetlioz Lq | US10071977 | Highly purifid pharmaceutical grade tasimelteon | Feb 12, 2035 | Vanda Pharms Inc |
| Hetlioz Lq | US10829465 | Highly purified pharmaceutical grade tasimelteon | Feb 12, 2035 | Vanda Pharms Inc |
| Hetlioz Lq | US11566011 | Highly purified pharmaceutical grade tasimelteon | Feb 12, 2035 | Vanda Pharms Inc |
| Hetlioz Lq | US11760740 | Highly purified pharmaceutical grade tasimelteon | Feb 12, 2035 | Vanda Pharms Inc |
| Hetlioz Lq | US12049457 | Highly purified pharmaceutical grade tasimelteon | Feb 12, 2035 | Vanda Pharms Inc |
| Hetlioz | US10610511 | Method of treatment | Oct 10, 2034 | Vanda Pharms Inc |
| Hetlioz | US11141400 | Method of treatment | Oct 10, 2034 | Vanda Pharms Inc |
| Hetlioz | US11786502 | Method of treatment | Oct 10, 2034 | Vanda Pharms Inc |
| Hetlioz Lq | US10610511 | Method of treatment | Oct 10, 2034 | Vanda Pharms Inc |
| Hetlioz Lq | US11141400 | Method of treatment | Oct 10, 2034 | Vanda Pharms Inc |
| Hetlioz Lq | US11786502 | Method of treatment | Oct 10, 2034 | Vanda Pharms Inc |
| Hetlioz | US9730910 | Treatment of circadian rhythm disorders | May 17, 2034 | Vanda Pharms Inc |
| Hetlioz Lq | US9730910 | Treatment of circadian rhythm disorders | May 17, 2034 | Vanda Pharms Inc |
| Hetlioz | US11918556 | Treatment of circadian rhythm disorders | Apr 07, 2033 | Vanda Pharms Inc |
| Hetlioz Lq | US11918556 | Treatment of circadian rhythm disorders | Apr 07, 2033 | Vanda Pharms Inc |
| Hetlioz | US10149829 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz | US10449176 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz | US10610510 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz | US10945988 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz | US10980770 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz | US11285129 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz | US11633377 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz | US11826339 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz | US11833130 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz | US11850229 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz | US11918557 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz | US12201604 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz | US8785492 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz | US9060995 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz | US9539234 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz | US9549913 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz | US9855241 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz | USRE46604 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz Lq | US10149829 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz Lq | US10610510 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz Lq | US10980770 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz Lq | US11285129 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz Lq | US11633377 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz Lq | US11826339 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz Lq | US11833130 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz Lq | US11850229 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz Lq | US11918557 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz Lq | US12201604 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz Lq | US9539234 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz | US5856529 | Benzofuran and dihydrobenzofuran melatonergic agents |
Dec 09, 2022
(Expired) | Vanda Pharms Inc |
| Hetlioz Lq | US5856529 | Benzofuran and dihydrobenzofuran melatonergic agents |
Dec 09, 2022
(Expired) | Vanda Pharms Inc |
Tasimelteon's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List